From validated PLIF cage design to scalable additive manufacturing
AM is established. Now it has to deliver.
In spine, additive manufacturing no longer needs an introduction.
The question for OEMs today is not whether to use AM, but how to turn an AM design into a robust, qualified, and scalable product. Pedicle screws, SI joint fusion devices, interbody cages, expandable implants, and patient-specific solutions are pushing the technology further every day. More complex geometries, advanced lattice structures, and functional integration also bring new challenges in validated designs, process control, post-processing, inspection, and validation.
Because printing the implant is only the beginning. Making it reproducibly, at the required quality and ready for a regulated market is what really matters.
PLIF cage mass FAE-driven design
As you know, designing for additive manufacturing, qualifying porous titanium structures, and scaling from first article to validated series production are different disciplines than traditional manufacturing.
It demands deep process control, materials science expertise, and regulatory rigor, most of it invisible in the end product, but essential to turn innovation into clinical benefits.
In this regard, the company WIMPULSE (https://www.wimpulse.tech/) has developed a unique process to support FDA submissions for 3D-printed medical devices, enabling evidence- and risk-based design for additive manufacturing (DFAM).
The benefit is a well-defined environment, backed by clear worst-case definitions and supported by algorithmic approaches.
In summary, it is a mass FEA process that enables faster regulatory clearance.
The FDA's "Technical Considerations for Additive Manufactured Medical Devices, " created back in 2017, are embedded directly into the DFAM process, resulting in a validated design that is ready to be manufactured in accordance with the manufacturer's capabilities and considering regulatory compliance.
All findings are then directly integrated into a technical file ready for 510K submission.
m4m end-to-end manufacturing workflow
After successful completion of the DFAM process, these geometries are then integrated into m4m's end-to-end manufacturing workflow, enabling spinal implants to be produced under a validated framework and to the demanding precision and economics the application requires.
The resolution of the printed geometries remains a key point of interest.
Combined with CNC post-processing, this enables additional possibilities for precision and geometric manufacturing.
Scaling of additive-manufactured spine cages
Scaling matters when delivering a high-performing spine device. But scaling is not only about producing more parts, it is about achieving repeatable quality at a competitive cost per implant.
OEMs therefore need manufacturing partners that combine precision, process control, capacity, and attractive unit economics.
The latest-generation Atlix (formerly TRUMPF) T2000 dual-laser platform lays the groundwork for m4m to support spine OEMs as both a primary and qualified second-source supplier.
Its flexible optical setup combines a 55 μm laser spot for high-precision features with an 80 μm spot and dual-laser configuration for higher productivity. This allows the manufacturing strategy to be adapted to the device: precision where it matters and productivity where it creates economic value.
For serial production, the objective is clear: increase parts per build, reduce machine time per implant, and distribute setup and quality costs across larger production batches. Based on optimized nesting, process parameters, and dual-laser productivity, m4m is targeting a 30–50% reduction in LPBF manufacturing cost per part compared with conventional lower-productivity setups.*
This is particularly relevant for interbody cages, expandable devices, SI fusion implants, and pedicle screws, where precision structures must be combined with economically scalable production.
More parts per build. Lower COGS per implant. Scalable, qualified production.
Target based on expected productivity improvements. Actual COGS reduction is device-, geometry-, batch-, and process-dependent and should be confirmed through production data.
Two Partners. One Integrated Path from Design to Production.
Wimpulse is a biomedical engineering firm offering global R&D services focused on the design of surgical implants and instruments. In partnership with key collaborators, WIMPULSE also extends its capabilities to Quality and Regulatory operations.
m4m additive manufacturing is an ISO 13485-certified, FDA-compliant Swiss CDMO built natively for metal additive manufacturing (LPBF) for medical devices. We take spine OEMs from concept to certified series production, with the process control, material science, and regulatory expertise that spine medical devices demand.
Commentaires